Debiopharm, NetTargets Partner to Advance Next-Gen ADCs

Debiopharm, a privately-owned biopharmaceutical company, has entered a strategic research collaboration with NetTargets, a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs).

This alliance unites NetTargets’ sophisticated artificial intelligence (AI) platform with Debiopharm’s proprietary MLINK technology to create a new paradigm in cancer treatment, aiming to deliver a decisive, dual-action blow against treatment-resistant tumors.

NetTargets’ proprietary AI platform integrates multi-omics data with deep neural network modeling to uncover synergistic mechanisms and accelerate drug discovery. It sifts through millions of potential compound combinations to identify synergistic pairings that are significantly more potent together than the sum of their individual effects. These AI-identified payloads will then be integrated into Debiopharm’s ADC technologies using MLINK Duo, a proprietary linker engineered specifically to carry two distinct payloads on a single antibody. This precision bio-engineering ensures the coordinated delivery and release of both warheads directly inside the cancer cell, maximizing their synergistic impact while minimizing systemic toxicity. This combination of AI-driven discovery and precision bio-engineering promises to produce a pipeline of dual-payload ADCs with a higher probability of clinical success against the most challenging cancers.

“To address the fundamental challenge of therapeutic resistance, we are moving beyond single-agent attacks,” explained Frédéric Lévy, Chief Scientific Officer at Debiopharm. “Our collaboration with NetTargets is about creating smarter and more precise therapies. We are using their powerful AI to find synergistic drug combinations for our ADC platforms, which allows us to rationally design therapies that are more effective. By attacking cancer on multiple fronts simultaneously, we not only increase the immediate efficacy of the treatment but also strategically minimize the cancer’s chances to adapt and develop resistance.”

“Our AI models are built to understand the complex biological networks that drive cancer,” commented Dr. Je-Hoon Song, CEO of NetTargets. “By simulating how different drug mechanisms interact, we can pinpoint unique vulnerabilities that would be impossible to find through traditional screening. Partnering with Debiopharm, a leader in ADC technology, allows us to translate these digital discoveries into tangible, life-saving therapies.”